Smith Hayes Advisers’s Myriad Genetics MYGN Stock Holding History

Smith Hayes Advisers’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-6,105	Closed	-$263K	–	312
2015 Q4	$263K	Sell	6,105 -48	-0.8%	-$2.03K	0.06%	268
2015 Q3	$231K	Sell	6,153 -704	-10%	-$25K	0.05%	266
2015 Q2	$233K	Sell	6,857 -72	-1%	-$2.45K	0.05%	284
2015 Q1	$245K	Buy	+6,929	New	+$248K	0.05%	279

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Smith Hayes Advisers's MYGN Position: Q1 2016 in Review

Smith Hayes Advisers sold out of Myriad Genetics (MYGN) in Q1 2016, closing a stake of 6,105 shares — an estimated $263K sold.

Smith Hayes Advisers first reported a position in MYGN in Q1 2015 and held it in 4 quarters. The position peaked at $263K in Q4 2015. 233 funds tracked by Wall St. Rank hold MYGN as of Q1 2016.

Smith Hayes Advisers reported no remaining Myriad Genetics position as of Q1 2016 after selling out during the quarter.
Smith Hayes Advisers sold 6,105 Myriad Genetics shares in Q1 2016, an estimated $263K.
Smith Hayes Advisers first reported a position in Myriad Genetics in Q1 2015 and held it in 4 quarters.
Smith Hayes Advisers's Myriad Genetics position peaked at $263K in Q4 2015.
233 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2016.

Based on Smith Hayes Advisers's 13F filing for Q1 2016, filed 16 May 2016.